Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience

Tuncer, Samuray; Tanyıldız, Burak; Başaran, Mert; Büyükbabanı, Nesimi; Dogan, Oner

doi:10.3109/02713683.2014.959605

Cited by 43 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab monotherapy therapy was employed more frequently in patients with advanced stage disease and a favourable response was seen in the majority of patients. Our results are consistent with previous reports (Mino et al, 2014;Tuncer et al, 2015) although the data on the use of rituximab in that setting is limited.…”

Section: Discussionsupporting

confidence: 92%

Dual institution experience of extranodal marginal zone lymphoma reveals excellent long‐term outcomes

Starr

Caimi

et al. 2016

Br J Haematol

View full text Add to dashboard Cite

Extranodal marginal zone lymphoma (EMZL) is a B-cell lymphoma arising from mucosa-associated lymphoid tissue (MALT). The disease characteristics, clinical course and treatment vary considerably based on site of involvement. Because long-term outcome data for EMZL are limited, we sought to describe the clinical details of a large number of patients with EMZL evaluated at the Case Comprehensive Cancer Center over a 12-year period to identify prognostic markers including the impact of site of involvement. We identified 211 cases of EMZL involving the stomach (30%), ocular adnexa (19%), lungs (16%) and intestines (9%). Initial treatment included antibiotics (18%), radiation (21%), rituximab (20%), chemotherapy (3%), rituximab + chemotherapy (7%), surgery (17%) or observation (8%). After a median follow-up of 44·3 months (range 2·2-214·9), median progression-free survival (PFS) was 68·2 months (95% confidence interval [CI] 54·5-111·3) and median overall survival (OS) has not been reached. Age >60 years, elevated lactate dehydrogenase level (LDH), ≥4 lymph node groups involvement, and high follicular lymphoma international prognostic index (FLIPI) were associated with inferior PFS/OS. In summary, patients with EMZL have excellent prognosis with median OS in excess of 10 years. Age, elevated LDH, advanced disease, and high FLIPI score are associated with worse outcomes.

show abstract

Section: Discussionsupporting

confidence: 92%

Dual institution experience of extranodal marginal zone lymphoma reveals excellent long‐term outcomes

Starr

Caimi

et al. 2016

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…The remaining patients required additional radiotherapy due to partial response or recurrence of disease. In this study, though, of the six patients whose disease was isolated to the conjunctiva (5 EMZL and 1 FL), five achieved complete response and remained free of local disease for a median follow-up of 25 months [124].…”

Section: Reviewmentioning

confidence: 99%

Classification, diagnosis, and management of conjunctival lymphoma

2019

View full text Add to dashboard Cite

Lymphoma is a malignant lymphoproliferative tumor that can involve the conjunctiva. Approximately 5–15% of all extranodal lymphomas are found in the ocular adnexal region, with approximately 25% of those involving the conjunctiva. Ninety-eight percent of conjunctival lymphomas arise from B-lymphocytes. The most common subtype of conjunctival lymphoma is extranodal marginal zone lymphoma (80%), followed by follicular lymphoma (8%), diffuse large B-cell lymphoma (3%) and mantle cell lymphoma (3%). Natural killer and T cells (NK/T) are rare causes of lymphoma. While most conjunctival lymphomas are localized to the ocular adnexa at the time of presentation, systemic examination and management are of key importance in the long-term care of the patient. This review outlines the classification, etiology, presentation, diagnosis, and management of conjunctival lymphoma. The novel use of high resolution optical coherence tomography, both as a diagnostic tool and as a means for ongoing evaluation during treatment, is illustrated. Treatment options discussed include external beam radiation, chemotherapy, immunotherapy, antibiotic therapy, and combination regimens. Future investigation of the etiology and pathogenesis of conjunctival lymphoma is expected to reveal opportunities for innovative and individualized therapeutic agents. Collaboration between multiple disciplines is key in the advancement of the field.

show abstract

“…NHL Subtypes Involving the Adnexal Structures: Ocular adnexal lymphoma (OAL), a rare form of NHL, comprises about 5-10% of all cases of OLs. [ 2 6 ] OAL most commonly affects the orbit (up to 40%) followed by the conjunctiva (35-40%) and the eyelids (up to 10%). [ 7 ] Of the various WHO subtypes of NHL, the three most common ones to affect the adnexal structures include extranodal marginal zone lymphoma (ENMZL), follicular lymphoma, and diffuse large B-cell lymphoma (DLCBL).…”

Section: Discussionmentioning

confidence: 99%

Ocular adnexal lymphoma presenting with visual loss

et al. 2016

View full text Add to dashboard Cite

Context:Elderly patients with visual loss often have age-related macular degeneration, diabetic retinopathy, glaucoma, and cataract as common causes of visual loss. Other less common etiologies should be considered, especially in those presenting with systemic associations.Case Report:The patient discussed in our review is an 80-year-old female, with a history of diabetic retinopathy and macular degeneration who presented with a sudden deterioration of vision. While this was initially attributed to diabetic retinopathy, she was eventually noted to have a salmon patch lesion in her conjunctiva, diagnosed on biopsy to be a diffuse large B-cell lymphoma.Conclusion:Because of the significant rate of disseminated disease among patients with lymphomas in the orbit that carries a worse prognosis, early diagnosis is essential to promote better overall survival of these patients. We describe here a patient diagnosed with conjunctival lymphoma associated with pronounced visual loss and review the literature on this subject.

show abstract

Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience

Cited by 43 publications

References 30 publications

Dual institution experience of extranodal marginal zone lymphoma reveals excellent long‐term outcomes

Dual institution experience of extranodal marginal zone lymphoma reveals excellent long‐term outcomes

Classification, diagnosis, and management of conjunctival lymphoma

Ocular adnexal lymphoma presenting with visual loss

Contact Info

Product

Resources

About